Research & Literature

Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.

Roehrborn CG, Oyarzabal Perez I, Roos EP, et al.

BJU international 2015; (116(3)):450-9 doi:10.1111/bju.13033.

EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

Gratzke C, Bachmann A, Descazeaud A, et al.

European urology 2015; (67(6)):1099-1109 doi:10.1016/j.eururo.2014.12.038.

Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP).

Robert G, Cornu JN, Fourmarier M, et al.

BJU international 2016; (117(3)):495-9 doi:10.1111/bju.13124.

Three year results of the prostatic urethral L.I.F.T. study.

Roehrborn CG, Rukstalis DB, Barkin J, et al.

The Canadian journal of urology 2015; (22(3)):7772-82.

The Impact of Increased Bladder Blood Flow on Storage Symptoms after Holmium Laser Enucleation of the Prostate.

Saito K, Hisasue S, Ide H, et al.

PloS one 2015; (10(6)):e0129111 doi:10.1371/journal.pone.0129111.

Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.

Yuan JQ, Mao C, Wong SY, et al.

Medicine 2015; (94(27)):e974 doi:10.1097/MD.0000000000000974.

Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

McVary KT, Gange SN, Gittelman MC, et al.

The Journal of urology 2016; (195(5)):1529-1538 doi:10.1016/j.juro.2015.10.181.

Assessment and management of male lower urinary tract symptoms (LUTS).

Abdelmoteleb H, Jefferies ER, Drake MJ

International journal of surgery (London, England) 2016; (25()):164-71.

[Pharmacological treatment of benign prostatic hyperplasia].

Oelke M, Martinelli E

Der Urologe. Ausg. A 2016; (55(1)):81-94; quiz 95-6 doi:10.1007/s00120-015-0011-3.

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Gacci M, Andersson KE, Chapple C, et al.

European urology 2016; (70(1)):124-133 doi:10.1016/j.eururo.2015.12.048.

Convective Water Vapor Energy for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

DeLay KJ, McVary KT

The Urologic clinics of North America 2016; (43(3)):371-5.

Management of Benign Prostatic Hyperplasia in Older Adults.

Woodard TJ, Manigault KR, McBurrows NN, et al.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2016; (31(8)):412-24 doi:10.4140/TCP.n.2016.412.

Combination of intravesical prostatic protrusion and resistive index is useful to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Suzuki T, Otsuka A, Ozono S

International journal of urology : official journal of the Japanese Urological Association 2016; (23(11)):929-933 doi:10.1111/iju.13188.

Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review.

Macey MR, Raynor MC

Seminars in interventional radiology 2016; (33(3)):217-23 doi:10.1055/s-0036-1586142.

New medical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and future perspectives.

Albisinni S, Biaou I, Marcelis Q, et al.

BMC urology 2016; (16(1)):58 doi:10.1186/s12894-016-0176-0.

Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study.

Gratzke C, Barber N, Speakman MJ, et al.

BJU international 2017; (119(5)):767-775 doi:10.1111/bju.13714.

Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.

Homma Y, Gotoh M, Kawauchi A, et al.

International journal of urology : official journal of the Japanese Urological Association 2017; (24(10)):716-729 doi:10.1111/iju.13401.

Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

Darson MF, Alexander EE, Schiffman ZJ, et al.

Research and reports in urology 2017; (9()):159-168 doi:10.2147/RRU.S143679.

[Medical treatment of micturition problems in men : what the general practitioner needs to know].

Vouga L, Benamran D, Iselin CE

Revue medicale suisse 2017; (13(585)):2069-2073.

Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.

Sebastianelli A, Russo GI, Kaplan SA, et al.

International journal of urology : official journal of the Japanese Urological Association 2018; (25(3)):196-205 doi:10.1111/iju.13498.

The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia.

Taoka R, Kakehi Y

Asian journal of urology 2017; (4(3)):158-163 doi:10.1016/j.ajur.2017.02.004.

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.

Kim EH, Brockman JA, Andriole GL

Asian journal of urology 2018; (5(1)):28-32 doi:10.1016/j.ajur.2017.11.005.

Prostatic stromal inflammation is associated with bladder outlet obstruction in patients with benign prostatic hyperplasia.

Inamura S, Ito H, Shinagawa T, et al.

The Prostate 2018; (78(10)):743-752 doi:10.1002/pros.23518.

Prostate Cancer in Primary Care.

Merriel SWD, Funston G, Hamilton W

Advances in therapy 2018; (35(9)):1285-1294 doi:10.1007/s12325-018-0766-1.

[Sexual consequences of BPH treatments].

Descazeaud A, Robert G, de La Taille A

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 2018; (28(15)):839-847 doi:10.1016/j.purol.2018.07.278.

Aquablation of the prostate: single-center results of a non-selected, consecutive patient cohort.

Bach T, Giannakis I, Bachmann A, et al.

World journal of urology 2019; (37(7)):1369-1375 doi:10.1007/s00345-018-2509-y.

Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes.

Gilling PJ, Barber N, Bidair M, et al.

Urology 2019; (125()):169-173 doi:10.1016/j.urology.2018.12.002.

[Fake News BPH - what is really true!]

Oelke M, Bschleipfer T, Höfner K

Der Urologe. Ausg. A 2019; (58(3)):271-283 doi:10.1007/s00120-019-0885-6.

[Diagnostic procedures and diagnostic strategy for lower urinary tract symptoms/benign prostatic hyperplasia : An overview].

Bschleipfer T, Oelke M, Rieken M

Der Urologe. Ausg. A 2019; (58(3)):238-247 doi:10.1007/s00120-019-0870-0.

Where can urodynamic testing help assess male lower urinary tract symptoms?

Gürbüz C, Drake MJ

Turkish journal of urology 2019; (45(3)):157-163 doi:10.5152/tud.2019.82783.

Is intravesical prostatic protrusion a risk factor for hydronephrosis and renal insufficiency in benign prostate hyperplasia patients?

Lu CH, Wu HHH, Lin TP, et al.

Journal of the Chinese Medical Association : JCMA 2019; (82(5)):381-384 doi:10.1097/JCMA.0000000000000088.

18 Years of Holmium Laser Enucleation of the Prostate: A Single Center Experience.

Ibrahim A, Alharbi M, Elhilali MM, et al.

The Journal of urology 2019; (202(4)):795-800 doi:10.1097/JU.0000000000000280.

Benign Prostatic Hyperplasia.

Langan RC

Primary care 2019; (46(2)):223-232 doi:10.1016/j.pop.2019.02.003.

Hematuria.

Peterson LM, Reed HS

Primary care 2019; (46(2)):265-273 doi:10.1016/j.pop.2019.02.008.

Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.

D'Agate S, Wilson T, Adalig B, et al.

World journal of urology 2020; (38(2)):463-472 doi:10.1007/s00345-019-02783-x.

Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.

Middleton LW, Shen Z, Varma S, et al.

JCI insight 2019; (5()).

Holmium Laser Enucleation of the Prostate After Failed UroLift: Surgical Considerations for the Management of Nonabsorbable Implants.

Parikh KA, Dora CD

Urology 2019; (132()):212 doi:10.1016/j.urology.2019.06.027.

ACR Appropriateness Criteria® Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia.

, Alexander LF, Oto A, et al.

Journal of the American College of Radiology : JACR 2019; (16(11S)):S378-S383 doi:10.1016/j.jacr.2019.05.031.

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).

Kaplan SA, Herschorn S, McVary KT, et al.

The Journal of urology 2020; (203(6)):1163-1171 doi:10.1097/JU.0000000000000738.

Is Holmium Laser Enucleation of the Prostate a Good Surgical Alternative in Benign Prostatic Hyperplasia Management? A Review Article.

Abedi A, Razzaghi MR, Rahavian A, et al.

Journal of lasers in medical sciences 2020; (11(2)):197-203 doi:10.34172/jlms.2020.33.

[Benign prostatic hyperplasia : New and treatment-relevant aspects from the DGU guidelines].

Bach T, Heitz M, Bruns T

Der Urologe. Ausg. A 2020; (59(5)):544-549 doi:10.1007/s00120-020-01184-y.

Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials.

Guo B, Chen X, Wang M, et al.

Medical science monitor : international medical journal of experimental and clinical research 2020; (26()):e923179 doi:10.12659/MSM.923179.

Real-World Safety and Effectiveness of Tadalafil in Patients with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Japanese Post-Marketing Surveillance Study.

Yamazaki H, Tsujimoto N, Koyanagi M, et al.

Pragmatic and observational research 2020; (11()):45-54 doi:10.2147/POR.S237821.

The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia.

Madersbacher S, Roehrborn CG, Oelke M

BJU international 2020; (126(3)):317-326 doi:10.1111/bju.15154.

Retrograde ejaculation after holmium laser enucleation of the prostate (HoLEP)-Impact on sexual function and evaluation of patient bother using validated questionnaires.

Gild P, Dahlem R, Pompe RS, et al.

Andrology 2020; (8(6)):1779-1786 doi:10.1111/andr.12887.

Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: A retrospective study.

Obinata D, Suzuki S, Yamanaka Y, et al.

Andrologia 2020; (52(11)):e13810 doi:10.1111/and.13810.

Superiority of Holmium Laser Enucleation of the Prostate over Transurethral Resection of the Prostate in a Matched-Pair Analysis of Bleeding Complications Under Various Antithrombotic Regimens.

Westhofen T, Schott M, Keller P, et al.

Journal of endourology 2021; (35(3)):328-334 doi:10.1089/end.2020.0321.

Changes in serum PSA after endoscopic enucleation of the prostate are predictive for the future diagnosis of prostate cancer.

Lambert E, Goossens M, Palagonia E, et al.

World journal of urology 2021; (39(7)):2621-2626 doi:10.1007/s00345-020-03444-0.

Holmium Laser Enucleation, Laparoscopic Simple Prostatectomy, or Open Prostatectomy: The Role of the Prostate Volume in terms of Operation Time.

Gunseren KO, Akdemir S, Çiçek MC, et al.

Urologia internationalis 2021; (105(3-4)):285-290 doi:10.1159/000511637.

Mechanical and Ablative Minimally Invasive Techniques for Male LUTS due to Benign Prostatic Obstruction: A Systematic Review according to BPH-6 Evaluation.

Cantiello F, Fimognari D, Di Mauro M, et al.

Urologia internationalis 2021; (105(9-10)):858-868 doi:10.1159/000514438.

Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

McVary KT, Gittelman MC, Goldberg KA, et al.

The Journal of urology 2021; (206(3)):715-724 doi:10.1097/JU.0000000000001778.

Aquablation versus holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia in medium-to-large-sized prostates (ATHLETE): protocol of a prospective randomised trial.

Müllhaupt G, Güsewell S, Schmid HP, et al.

BMJ open 2021; (11(5)):e046973 doi:10.1136/bmjopen-2020-046973.

Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.

Bhat A, Blachman-Braun R, Herrmann TRW, Shah HN

World journal of urology 2022; (40(4)):889-905 doi:10.1007/s00345-021-03771-w.

The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.

Jin R, Strand DW, Forbes CM, et al.

The Prostate 2021; (81(13)):944-955 doi:10.1002/pros.24190.

Is there concordance between overactive bladder and detrusor overactivity in men with predominant storage urinary symptoms referred to Functional Urology and Urodynamics Units?

Esteban-Fuertes M, Prieto-Chaparro L, Arlandis-Guzmán S, et al.

Actas urologicas espanolas 2021; doi:10.1016/j.acuro.2021.06.002.

Surgical treatment options for benign prostatic obstruction: beyond prostate volume.

Deyirmendjian C, Elterman D, Chughtai B, et al.

Current opinion in urology 2022; (32(1)):102-108 doi:10.1097/MOU.0000000000000937.

Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review.

Couteau N, Duquesne I, Frédéric P, et al.

Journal of clinical medicine 2021; (10(24)) doi:10.3390/jcm10245788.

Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells.

Tong Y, Guo YJ, Zhang Q, et al.

Asian journal of andrology 2022; (24(5)):513-520 doi:10.4103/aja2021114.

Impact of perioperative factors on nadir serum prostate-specific antigen levels after holmium laser enucleation of prostate.

Martos M, Katz JE, Parmar M, et al.

BJUI compass 2021; (2(3)):202-210 doi:10.1002/bco2.68.

Frailty and benign prostatic hyperplasia: The thrilling underlying impact.

Bellos TC, Tzelves LI, Manolitsis IS, et al.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2022; (94(3)):345-349 doi:10.4081/aiua.2022.3.345.

Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.

Abotsi E, Adanu KK, Bansah EC

African journal of primary health care & family medicine 2022; (14(1)):e1-e6 doi:10.4102/phcfm.v14i1.3736.

Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis.

Tsubouchi K, Arima H, Abe M, et al.

The Journal of urology 2023; (209(4)):665-674 doi:10.1097/JU.0000000000003209.

Case report of avascular necrosis of the glans penis after PAE embolization.

Liu J, Gong YY, Ran C, et al.

BMC urology 2023; (23(1)):31 doi:10.1186/s12894-023-01201-0.

Management of urethral strictures and stenosis caused by the endo-urological treatment of benign prostatic hyperplasia-a single-center experience.

Kore RN

Asian journal of urology 2023; (10(2)):137-143 doi:10.1016/j.ajur.2021.06.009.

Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis.

Cornu JN, Zantek P, Burtt G, et al.

European urology 2023; (83(6)):534-547 doi:10.1016/j.eururo.2023.02.028.

Assessment and management of lower urinary tract symptoms in men.

Dawson BC

Nursing standard (Royal College of Nursing (Great Britain) : 1987) 2023; doi:10.7748/ns.2023.e11996.

How Would You Manage This Patient With Benign Prostatic Hyperplasia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.

Smetana GW, Smith CC, Singla A, Libman H

Annals of internal medicine 2023; (176(4)):545-555 doi:10.7326/M23-0113.

Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms.

Gravas S, Gacci M, Gratzke C, et al.

European urology 2023; (84(2)):207-222 doi:10.1016/j.eururo.2023.04.008.

[Diagnostic work-up of benign prostatic hyperplasia : The German S2e-guideline 2023 part 1].

Oelke M, Abt SD, Becher KF, et al.

Urologie (Heidelberg, Germany) 2023; (62(8)):805-817 doi:10.1007/s00120-023-02142-0.

Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia.

Hata J, Harigane Y, Matsuoka K, et al.

International journal of molecular sciences 2023; (24(14)) doi:10.3390/ijms241411634.

Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia.

Pollack AS, Kunder CA, Brazer N, et al.

JCI insight 2024; (9(2)).

Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement.

Osman T, Elawady H, Fawaz K, et al.

International urology and nephrology 2024; (56(6)):1811-1816 doi:10.1007/s11255-023-03912-7.

Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI-RS 2023.

Tarcan T, Hashim H, Malde S, et al.

Neurourology and urodynamics 2024; (43(6)):1447-1457 doi:10.1002/nau.25435.

Minimally invasive interventions for lower urinary tract symptoms: What sits between medical therapy and transurethral resection of the prostate.

Yanada BA, Homewood D, Reeves F, Bolton D

Australian journal of general practice 2024; (53(5)):258-263 doi:10.31128/AJGP-10-23-7007.

Transurethral water vapour thermal therapy for benign prostatic hyperplasia under local anaesthesia alone: initial experience in Chinese patients.

Lo KL, Mok A, Ko ICH, et al.

Hong Kong medical journal = Xianggang yi xue za zhi 2024; (30(3)):227-232 doi:10.12809/hkmj2210330.

Application of Urethral Contrast Computed Tomography Three-Dimensional Imaging in the Postoperative Assessment of Prostate Hyperplasia.

Zhang X, Zhou C, Li W, et al.

American journal of men's health 2024; (18(3)):15579883241258319 doi:10.1177/15579883241258319.

[Benign prostatic hyperplasia].

Infante Hernández S, Gómez Rivas J, Moreno Sierra J

Medicina clinica 2024; (163(8)):407-414 doi:10.1016/j.medcli.2024.04.014.

Acute Urinary Retention and Severe Hyponatremia in a Patient With a Large Intramural Uterine Fibroid.

Jannat H, Hussain SS, Ahmad H

Cureus 2024; (16(9)):e68587 doi:10.7759/cureus.68587.

Evaluation of Peri-Operative Outcomes after Prostatic Urethral Lift with Emphasis on Urodynamic Changes, Symptom Improvement and Sexual Function.

Lombardo R, Santarelli V, Turchi B, et al.

Diagnostics (Basel, Switzerland) 2024; (14(19)) doi:10.3390/diagnostics14192110.

A case of rapidly progressive prostate cancer with bone and lymph node metastasis after contact laser vaporization for benign prostatic hyperplasia.

Muraoka K, Fujisaki A, Uchida K, et al.

IJU case reports 2025; (8(1)):47-51 doi:10.1002/iju5.12806.

Impact of Endoscopic Bladder Outlet Procedures on Medical and Surgical Retreatment: A Large Population Analysis.

Helman T, Patil D, Marthi S, Browne B

Journal of endourology 2025; (39(6)):608-616 doi:10.1089/end.2024.0741.

Should magnetic resonance imaging be considered in every patient before a bladder outflow obstruction procedure?

Donkov I, Chatzikrachtis N, Chatterjee A, et al.

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 2025; (97(2)):13935 doi:10.4081/aiua.2025.13935.

Stromal SRD5A2 promotes prostate growth through WNT5A-LEF1-IGF1 signaling in benign prostatic hyperplasia.

Sharkey C, Gu B, Long X, et al.

bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.05.22.655540.

Lower Urinary Tract Symptoms in Men: A Review.

Wei JT, Dauw CA, Brodsky CN

JAMA 2025; (334(9)):809-821 doi:10.1001/jama.2025.7045.

Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement.

Akgul B, Tozsin A, Aydın A, et al.

World journal of urology 2025; (43(1)):494 doi:10.1007/s00345-025-05884-y.

Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH).

Anract J, Klein C, Sarrazin C, et al.

The French journal of urology 2025; (35(11)):102952 doi:10.1016/j.fjurol.2025.102952.

Management of acute urinary retention in men with benign prostatic hyperplasia: Literature review and guidelines from the French Urological Association Male LUTS Panel (CTMH).

Pinar U, Gas J, Sarrazin C, et al.

The French journal of urology 2025; (35(11)):102953 doi:10.1016/j.fjurol.2025.102953.

Five-year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-world Analysis Using Epic Cosmos.

Carletti F, Tamborino F, Turcan A, et al.

European urology focus 2026; (12(3)):383-392 doi:10.1016/j.euf.2026.01.003.

Modified water vapor thermal therapy for large-volume benign prostatic hyperplasia.

Lu Q, Zhu G, Liu J, et al.

BMC urology 2026; (26(1)).

Which investigations should be performed after a first episode of urinary tract infection in men?

Soudais B, Bruyère F, Forestier E, et al.

Infectious diseases now 2026; (56(6S)):105315 doi:10.1016/j.idnow.2026.105315.